Sunitinib in urothelial cancer: Clinical, pharmacokinetic, and immunohistochemical study of predictors of response

European Urology

Volumn 60, Issue 2, 2011, Pages 344-349

  Gallagher, David J ^a   Al Ahmadie, Hikmat ^b   Ostrovnaya, Irina ^b   Gerst, Scott R ^b   Regazzi, Ashley ^b   Garcia Grossman, Ilana ^b   Riches, Jamie ^b   Gounder, Sivaraman K ^b   Flaherty, Anne Marie ^b   Trout, Alisa ^b   Milowsky, Matthew I ^b,c   Bajorin, Dean F ^b,c  

^a MATER PRIVATE HOSPITAL   (Ireland)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biomarkers; Predictive; Sunitinib; Transitional cell carcinoma; Urothelial cancer

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UROGENITAL TRACT CANCER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANGIOGENESIS INHIBITORS; BLOOD PRESSURE; CARCINOMA, TRANSITIONAL CELL; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTENSION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INDOLES; LOGISTIC MODELS; NEW YORK CITY; PHOSPHOPROTEINS; PHOSPHORYLATION; PYRROLES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS; UROTHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79959571422     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.05.034     Document Type: Article

References (30)

1. H. von der Maase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
2. H. von der Maase, L. Sengelov, and J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608 (Pubitemid 46224062)
3. D.J. Gallagher, and N. Kemeny Second-line management of metastatic colorectal cancer Clin Colorectal Cancer 7 2008 25 32 (Pubitemid 351252448)
4. D.J. Gallagher, M.I. Milowsky, and S.R. Gerst Phase II study of sunitinib in patients with metastatic urothelial cancer J Clin Oncol 28 2010 1373 1379
5. D.F. Bajorin, P.M. Dodd, and M. Mazumdar Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 17 1999 3173 3181 (Pubitemid 29470648)
6. J. Bellmunt, J. Albanell, and L. Paz-Ares Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine Cancer 95 2002 751 757 (Pubitemid 34839666)
7. J. Bellmunt, T.K. Choueiri, and R. Fougeray Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens J Clin Oncol 28 2010 1850 1855
8. N. Murukesh, C. Dive, and G.C. Jayson Biomarkers of angiogenesis and their role in the development of VEGF inhibitors Br J Cancer 102 2010 8 18
9. B.E. Houk, C.L. Bello, B. Poland, L.S. Rosen, G.D. Demetri, and R.J. Motzer Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 66 2010 357 371
10. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434 (Pubitemid 36910021)
11. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111 (Pubitemid 350296300)
12. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
13. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
14. J. Hasan, R. Byers, and G.C. Jayson Intra-tumoural microvessel density in human solid tumours Br J Cancer 86 2002 1566 1577 (Pubitemid 34628110)
15. B.H. Bochner, R.J. Cote, and N. Weidner Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis J Natl Cancer Inst 87 1995 1603 1612
16. A.M. Jubb, H.I. Hurwitz, and W. Bai Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer J Clin Oncol 24 2006 217 227 (Pubitemid 46622051)
17. S.B. Wedam, J.A. Low, and S.X. Yang Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol 24 2006 769 777 (Pubitemid 46622044)
18. G. Sonpavde, W. Jian, H. Liu, M.F. Wu, S.S. Shen, and S.P. Lerner Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model Urol Oncol 27 2009 391 399
19. S. Kourembanas, R.L. Hannan, and D.V. Faller Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells J Clin Invest 86 1990 670 674 (Pubitemid 20271905)
20. N. de Paulsen, A. Brychzy, and M.C. Fournier Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis Proc Natl Acad Sci U S A 98 2001 1387 1392 (Pubitemid 32165508)
21. B.I. Rini, and M.B. Atkins Resistance to targeted therapy in renal-cell carcinoma Lancet Oncol 10 2009 992 1000
22. P.H. Patel, R.S. Chadalavada, and N.M. Ishill Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) J Clin Oncol 2008 26 Abstract 5008
23. S.K. Tickoo, M.I. Milowsky, and N. Dhar Hypoxia inducible factor (HIF) and mammalian target of rapamycin (mTOR) pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications BJU Int 107 2011 844 849
24. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664 (Pubitemid 46797944)
25. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048 (Pubitemid 350106711)
26. S.P.M. Tejpar, Y. Humblet, and J.B. Vermorken Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan- refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVEREST experience (preliminary data) J Clin Oncol 2008 26 Abstract 4001
27. M.E. Lacouture, E.P. Mitchell, and B. Piperdi Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 2010 1351 1357
28. A. Lievre, J.B. Bachet, and V. Boige KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 2008 374 379 (Pubitemid 351171687)
29. M. Peeters, S. Siena, and E. Van Cutsem Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy Cancer 115 2009 1544 1554
30. C. Kim, and S. Paik Gene-expression-based prognostic assays for breast cancer Nat Rev Clin Oncol 7 2010 340 347